Back to Results
First PageMeta Content
Aethlon Medical / Exosome / Hepatitis / Interferon / Clinical trial / Alternative medicine / Management of cancer / Virus / Health / Biology / Medicine


R E P R I N T E D F R O M A U G U S T
Add to Reading List

Document Date: 2015-06-16 14:52:42


Open Document

File Size: 256,53 KB

Share Result on Facebook

City

San Diego / /

Company

ABC / Aethlon Medical Inc. / NBC / Mission Labs Inc. / James Joyce & Associates / JAMES A. JOYCE / Pharmasset / London Zurich Securities Inc. / CNN / /

Country

United States / India / /

Currency

USD / /

Event

Earnings Guidance / /

Facility

Medanta Medicity Institute / University Center Ln. / The University of Maryland / /

IndustryTerm

investment community communications / device technology / media outlets / therapeutic devices / platform technology / cancer treatment / adaptive dialysis-like affinity platform technology / device solutions / manufacturing / treatment for hepatitis C / hepatitis C treatment / /

MedicalCondition

HIV / metastasis / hepatitis C / infectious viral pathogens / sepsis / cancer / tumors / disease / actively conducting hepatitis C / market disease / hepatitis C. We / infectious disease / /

MedicalTreatment

immunotherapies / chemotherapies / drug therapies / drug therapy / dialysis / /

Organization

Defense Advanced Research Projects Agency / University of Maryland / U.S. government / Denver Broncos Football Club / Congress / Medanta Medicity Institute / FDA / National Football League / /

Person

JAMES A. JOYCE / /

Position

Chairman and Chief Executive Officer / tax loss carry forward / CEO / Chairman & CEO / member / /

Product

Avastin / /

ProgrammingLanguage

C / /

ProvinceOrState

Maryland / California / /

PublishedMedium

the journal Nature / /

SportsLeague

National Football League / /

Technology

adaptive dialysis-like affinity platform technology / platform technology / device technology / genotype / Dialysis / /

URL

www.aethlonmedical.com / /

SocialTag